Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (surface antigen, inactivated, high dose) + elasomeran
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Efluelda + Spikevax is a co-administration regimen consisting of two distinct, approved vaccines: Efluelda (the European brand name for Fluzone High-Dose) and Spikevax (Moderna's COVID-19 vaccine). Efluelda is a quadrivalent inactivated influenza vaccine containing a higher dose of hemagglutinin (60 µg per strain) compared to standard-dose vaccines, specifically designed to elicit a stronger immune response in adults aged 65 and older. Spikevax is an mRNA-based vaccine that encodes the prefusion-stabilized spike protein of SARS-CoV-2. In clinical research, this regimen is used as an active comparator to evaluate the effectiveness of investigational combination vaccines, such as Moderna's mRNA-1083 (mCombriax), which aims to provide protection against both seasonal influenza and COVID-19 in a single injection.
- Brand names
- Fluzone High-Dose
- Other names
- Efluelda + Spikevaxelasomeran + influenza vaccine (surface antigen, inactivated, high dose)elasomeranmRNA-1273mRNA1273mRNA 1273
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on influenza vaccine (surface antigen, inactivated, high dose) + elasomeran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (surface antigen, inactivated, high dose) + elasomeran.